CRISPR Therapeutics AG (FRA:1CG) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1CG CRISPR Therapeutics AG FRA:1CG
32 GF Score
Price €45.62
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CRISPR Therapeutics AG  (FRA:1CG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CRISPR Therapeutics AG Cyclically Adjusted PB Ratio Related Terms


CRISPR Therapeutics AG Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted PB Ratio Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.02

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.88 3.83 3.02 2.71 0.00

FRA:1CG vs MANE, EWTX, CAI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio falls into.


FRA:1CG
32GF Score
CRISPR Therapeutics AG FRA:1CG
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CRISPR Therapeutics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, CRISPR Therapeutics AG's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.684/108.5600*108.5600
=15.684

Current CPI (Jun. 2026) = 108.5600.

CRISPR Therapeutics AG Quarterly Data

Book Value per Share CPI Adj_Book
201609 -1.401 99.604 -1.527
201612 5.557 99.380 6.070
201703 5.053 100.040 5.483
201706 4.397 100.285 4.760
201709 3.672 100.254 3.976
201712 3.910 100.213 4.236
201803 5.044 100.836 5.430
201806 4.822 101.435 5.161
201809 6.937 101.246 7.438
201812 6.648 100.906 7.152
201903 6.386 101.571 6.825
201906 6.082 102.044 6.470
201909 9.738 101.396 10.426
201912 13.910 101.063 14.942
202003 13.170 101.048 14.149
202006 12.626 100.743 13.606
202009 16.153 100.585 17.434
202012 18.508 100.241 20.044
202103 20.026 100.800 21.568
202106 28.407 101.352 30.427
202109 27.935 101.533 29.869
202112 27.582 101.776 29.421
202203 26.340 103.205 27.707
202206 25.426 104.783 26.343
202209 25.221 104.835 26.117
202212 22.550 104.666 23.389
202303 21.968 106.245 22.447
202306 21.118 106.576 21.511
202309 20.383 106.570 20.764
202312 21.570 106.461 21.995
202403 22.599 107.355 22.853
202406 21.639 107.991 21.753
202409 20.479 107.468 20.687
202412 21.520 107.128 21.808
202503 19.592 107.722 19.744
202506 16.787 108.075 16.862
202509 17.390 107.710 17.527
202512 17.115 107.200 17.332
202603 16.284 108.060 16.359
202606 15.684 108.560 15.684

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
32GF Score

Get the complete analysis for FRA:1CG

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.62
Price